Cenicriviroc + Pioglitazone = Unknown or no reaction

Effect on Concentration

Cenicriviroc
Decrease
Applies within class?
No
Pioglitazone
Decrease
Applies within class?
No

Pharmacologic Effects

Cenicriviroc
Effect
N/A
Applies within class?
No
Pioglitazone
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

Concomitant use of CVC and PGZ resulted in slight decreases in PK of both CVC and PGZ. However, the magnitude of these interactions was not clinically meaningful and no dose adjustment is required when co-administering two drugs.

Sources

Cenicriviroc vs pioglitazone ^

Study Design

In phase 1, multiple-dose, open-label, 3-period fixed-sequence crossover study, healthy subjects (n=20) were randomized to treatment sequence A or B.Sequence A (n=10): subjects received Cenicriviroc (CVC) 150 mg once daily for 10 days (Period 1). After a 10-day washout, subjects received pioglitazone (PGZ) 45 mg once daily for 10 days (Period 2) followed by coadministration of CVC 150 mg and PGZ 45 mg once daily for 10 days (Period 3).Sequence B (n=10): subjects received PGZ 45 mg once daily for 10 days (Period 1). After a 10-day washout, subjects received CVC 150 mg once daily (Period 2) followed by coadministration of CVC 150 mg and PGZ 45 mg once daily for 10 days (Period 3).

Study Results

Co-administration of CVC with PGZ resulted in slightly decreased PK parameters of CVC. The geometric mean ratios (GMRs; CVC+PGZ /CVC) [90% CIs] of CVC were: 0.86 [0.73, 1.02] for Cmax, 0.84 [0.69, 1.01] for AUC, 0.98 [0.81, 1.19] for Cmin.Administration of CVC slightly decreased PK parameters of PGZ, and it did not significantly affect PK of either M-III or M-IV, active metabolites of PGZ.GMRs (CVC+PGZ /PGZ) [90% CIs] of PGZ were: 0.80 [0.73, 0.87] for Cmax, 0.82 [0.77, 0.88] for AUC, 1.01 [0.92, 1.11] for CminPK parameters of both M-III and M-IV were within "no-effect" limits (80-125%); however, no specific values were indicated.Study treatments were generally well tolerated. The majority of adverse events (AEs) were mild severity and there were no serious AEs. The most frequent AEs were headache and fatigue.

Study Conclusions

References

Gottwald MD, C Galloway, M Willett, et al. Cenicriviroc and pioglitazone co-administration shows favorable pharmacokinetics and safety in healthy subjects. 66th Annual Meeting Of The American Association For The Study Of Liver Diseases (aasld). San Francisco, CA. ; 2015.